La Jolla Pharmaceutical (LJPC) Stock: Continuing Its Run For The Top

La Jolla Pharmaceutical Company (NASDAQ: LJPC) is climbing in the market yet again today, following up on the incredible gains that the stock saw yesterday. The gains follow the company’s announcement surrounding clinical data, which led to nearly 100% gains yesterday, followed by 20% gains today in the premarket.

LJPC Stock Gains On Clinical Data

As mentioned above, La Jolla Pharmaceutical had an incredible day in the market yesterday, followed by strong gains today after announcing clinical data. The data came from an interim analysis of its Phase 2 study of LJPC-401.

LJPC-401 is being assessed as a potential option for patients with hereditary hemochromatosis.

In the release, the company said that the primary efficacy endpoint led to statistical significance. Patients treated with the drug saw a mean reduction in TSAT of 42% compared to placebo patients with a reduction of 6%.

Also, the requirement and frequency of plebotomy procedures, a key secondary endpoint also led to statistical significance. Those treated with LJPC-401 required 0.06 phlebotomies per month with placebo patients requiring 0.41 per month.

The treatment also proved to be safe and well-tolerated. In a statement, Jeff Vacirca, M.D., Chief of Clinical Research at New York Cancer & Blood Specialists and an Investigator in the LJPC study, had the following to offer:

The robustness of this early readout supporting further development of LJPC-401 is very encouraging. There have been no new treatment modalities introduced for patients with hereditary hemochromatosis in more than a decade. In light of the negative impact that repeated phlebotomy procedures have on patient quality-of-life, patients would welcome a pharmacologic treatment that they can self-administer and that addresses the underlying pathophysiology of the disease.

What We’ll Be watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on LJPC. In particular, we’re interested in following the continued development of LJPC-401 as the treatment seems to be yielding promising results. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

Leave a Comment